STOCK TITAN

Elutia Inc. reported $12.3M in revenue and $53.4M in net income for fiscal 2025. See the full ELUT financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

Elutia will meet investors and present on its drug-eluting biomatrix technology at two New York conferences in September 2026.

(Moderate)
(Neutral)
Tags

Elutia (ELUT) will participate in two investor conferences in New York City in September 2026. Management will attend the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference on September 10, 2026, for one-on-one investor meetings. The company will also present and hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 15-16, 2026. A webcast of Elutia’s presentation on its drug-eluting biomatrix technology and its role in addressing post-surgical infections in plastic and reconstructive surgeries will be available on-demand following a live presentation beginning at 7:00 a.m. EDT on Friday, September 11, 2026.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Market Context

On August 18, 2026, Elutia's SimpliDerm sale announcement was followed by a -5.01% 24-hour move, sho...
Analysis

On August 18, 2026, Elutia's SimpliDerm sale announcement was followed by a -5.01% 24-hour move, showing prior news sensitivity. This notice adds scheduling information; investors can watch for substantive updates alongside the Nasdaq $1.00 minimum-bid issue.

Key Figures

Lake Street conference edition: 10th annual Lake Street meeting date: September 10, 2026 H.C. Wainwright conference edition: 28th annual +3 more
6 metrics
Lake Street conference edition 10th annual Lake Street Capital Markets Big Ideas Growth Conference
Lake Street meeting date September 10, 2026 One-on-one investor meetings
H.C. Wainwright conference edition 28th annual H.C. Wainwright Global Investment Conference
H.C. Wainwright conference dates September 15-16, 2026 Presentation and one-on-one investor meetings
Presentation time 7:00am Eastern Daylight Time September 11, 2026 webcast
Presentation date September 11, 2026 H.C. Wainwright presentation

Historical Context

5 past events · Latest: Aug 18 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Aug 18 SimpliDerm sale Positive -5.0% Completed sale added cash and focused resources on NXT-41x.
Aug 13 2Q26 earnings Positive +6.0% Funding, surgeon interest, regulatory timelines, and quarterly results were reported.
Aug 13 Loan financing Positive +6.0% Avenue Capital provided financing, with an additional tranche tied to FDA clearance.
Jul 31 Earnings date Neutral -5.3% The company scheduled release of second-quarter financial results.
Jul 16 SimpliDerm agreement Positive +0.0% Elutia signed an agreement to sell SimpliDerm for up to $11 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

ELUT's recent reactions diverged from positive transaction news twice but aligned with positive financing and earnings-related announcements.

Key Terms

drug-eluting biomatrix technologies
1 terms
drug-eluting biomatrix technologies technical
"Elutia Inc. (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix technologies"
Drug-eluting biomatrix technologies are engineered biological or biocompatible materials—often polymers or gels—that carry and release pharmaceutical agents slowly and locally from a device or implant. They matter to investors because they are the technical core of products that combine a medical device with controlled drug delivery, so their regulatory approval, manufacturing scalability, durability, and intellectual property can strongly affect a product’s clinical use, market size, and revenue potential; think of the matrix as a timed-release capsule built into a device.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, Matthew Ferguson, Chief Financial Officer, and Dr. Michelle Williams, Chief Scientific Officer, will participate in two upcoming investor conferences.

Lake Street Capital Markets 10th Annual Big Ideas Growth Conference
Elutia will host one-on-one meetings with investors at the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference at the Metropolitan Club in New York City on September 10, 2026. To schedule a one-on-one meeting, institutional investors may contact their Lake Street representative.

H.C. Wainwright 28th Annual Global Investment Conference
Elutia will also present and host one-on-one meetings with investors at the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York City on September 15-16, 2026.

During the presentation, management will discuss how Elutia is working to address post-surgical infection in plastic and reconstructive surgeries—one of the most significant challenges facing patients and surgeons—through its drug-eluting biomatrix technology designed to support safer, more reliable reconstructive outcomes.

The presentation will begin at 7:00am Eastern Daylight Time on Friday, September 11, 2026, and can be accessed on-demand here: Webcast. Elutia will also host one-on-one meetings with investors on September 15-16, 2026. To schedule a one-on-one meeting, visit H.C. Wainwright.

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia's mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Elutia Investor Relations
ir@elutia.com


FAQ

When will Elutia (ELUT) attend the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference?

Elutia will participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference on September 10, 2026, at the Metropolitan Club in New York City, where the company will host one-on-one meetings with institutional investors.

How can investors schedule one-on-one meetings with Elutia (ELUT) at the Lake Street conference?

Institutional investors who wish to schedule one-on-one meetings with Elutia at the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference may contact their Lake Street representative to arrange a meeting.

What are the dates and location of Elutia’s participation in the H.C. Wainwright 28th Annual Global Investment Conference?

Elutia will present and host one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 15-16, 2026, at the Lotte New York Palace Hotel in New York City.

When is Elutia’s webcast presentation at the H.C. Wainwright Global Investment Conference and how can it be accessed?

Elutia’s presentation will begin at 7:00 a.m. Eastern Daylight Time on Friday, September 11, 2026, and can be accessed on-demand via a webcast link provided by the conference organizer.

How can investors arrange one-on-one meetings with Elutia (ELUT) at the H.C. Wainwright conference?

To schedule one-on-one meetings with Elutia during the H.C. Wainwright 28th Annual Global Investment Conference on September 15-16, 2026, investors are directed to visit H.C. Wainwright to arrange a meeting.

What topic will Elutia (ELUT) discuss during its H.C. Wainwright conference presentation?

Elutia’s management will discuss how the company is working to address post-surgical infection in plastic and reconstructive surgeries through its drug-eluting biomatrix technology, which is designed to support safer, more reliable reconstructive outcomes.